| scholarly article | Q13442814 |
| P2093 | author name string | Alex Freeman | |
| Alison J Birtle | |||
| BAUS Section of Oncology Cancer Registry | |||
| Heather A Payne | |||
| John R W Masters | |||
| Stephen J Harland | |||
| P2860 | cites work | Chemotherapy for androgen-independent prostate cancer. | Q34800031 |
| Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature | Q35225436 | ||
| Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center | Q36768812 | ||
| Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm | Q40915955 | ||
| Evaluation and follow-up of patients with N1-3 M0 or NXM1 prostate cancer in phase III trials | Q41438387 | ||
| M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL. | Q43666043 | ||
| The usefulness of prostate-specific antigen and prostatic acid phosphatase in clinical practice. | Q43812423 | ||
| Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? | Q48013591 | ||
| High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group. | Q54164587 | ||
| A major solid undifferentiated carcinoma pattern correlates with tumour progression in locally advanced prostatic carcinoma | Q67555866 | ||
| Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia | Q67655394 | ||
| Benefits of combination therapy with flutamide in patients relapsing after castration | Q68144932 | ||
| Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate | Q69003522 | ||
| Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate | Q71624975 | ||
| Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? | Q71701739 | ||
| Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report | Q72182752 | ||
| A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen | Q73707411 | ||
| Low PSA metastatic androgen- independent prostate cancer | Q74163978 | ||
| Bilateral orchiectomy with or without flutamide for metastatic prostate cancer | Q77374114 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metastatic prostate carcinoma | Q55779807 |
| P304 | page(s) | 2362-2367 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients | |
| P478 | volume | 98 |
| Q38399316 | A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes. |
| Q64234670 | Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia |
| Q37197722 | Evolving perspectives of the role of novel agents in androgen-independent prostate cancer |
| Q37008842 | Lethal Prostate Cancer in the PLCO Cancer Screening Trial. |
| Q28253671 | Lineage dependency and lineage-survival oncogenes in human cancer |
| Q48255389 | Primary bone lymphoma presenting as skeletal lesions in a patient recently treated for prostate cancer |
| Q41356340 | Prostate adenocarcinoma metastases to the testis and brain: case report and review of the literature |
| Q36344910 | Prostatic meningeal carcinomatosis with low serum level of prostate-specific antigen |
| Q36502875 | Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report |
Search more.